Skip Navigation

Publicaciones covid-9

Inicio Navegar por Acerca de Recomendaciones Ayuda
Búsqueda avanzada

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial

John Frater*, Katie J Ewer*, Ane Ogbe*, Mathew Pace*, Sandra Adele, Emily Adland, Jasmini Alagaratnam, Parvinder K Aley, Mohammad Ali,
M Azim Ansari, Anna Bara, Mustapha Bittaye, Samantha Broadhead, Anthony Brown, Helen Brown, Federica Cappuccini, Enya Cooney,
Wanwisa Dejnirattisai, Christina Dold, Cassandra Fairhead, Henry Fok, Pedro M Folegatti, Jamie Fowler, Charlotte Gibbs, Anna L Goodman, Daniel Jenkin, Mathew Jones, Rebecca Makinson, Natalie G Marchevsky, Yama F Mujadidi, Hanna Nguyen, Lucia Parolini, Claire Petersen, Emma Plested, Katrina M Pollock, Maheshi N Ramasamy, Sarah Rhead, Hannah Robinson, Nicola Robinson, Patpong Rongkard, Fiona Ryan, Sonia Serrano, Timothy Tipoe, Merryn Voysey, Anele Waters, Panagiota Zacharopoulou, Eleanor Barnes, Susanna Dunachie, Philip Goulder, Paul Klenerman, Gavin R Screaton, Alan Winston, Adrian V S Hill*, Sarah C Gilbert*, Andrew J Pollard*, Sarah Fidler*, Julie Fox*, Teresa Lambe*,
for the Oxford COVID Vaccine Trial Group
?  Evaluación: (not yet rated)
Resumen

Background

Data on vaccine immunogenicity against SARS-CoV-2 are needed for the 40 million people globally living with HIV who might have less functional immunity and more associated comorbidities than the general population. We aimed to explore safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV.

Methods

In this single-arm open-label vaccination substudy within the protocol of the larger phase 2/3 trial COV002, adults aged 18–55 years with HIV were enrolled at two HIV clinics in London, UK. Eligible participants were required to be on antiretroviral therapy (ART), with undetectable plasma HIV viral loads (0·05 for all analyses).

Interpretation

In this study of people with HIV, ChAdOx1 nCoV-19 was safe and immunogenic, supporting vaccination for those well controlled on ART.
Procedencia del autor
Texto completo
Tipo de documento
Especialidad(es)
Publicado en el sitio 2021-07-23 12:12:47
Reportar cualquier problema con este Recurso

Comentarios

(aún no hay comentarios disponibles para este recurso)

Al DÃA - Enfermedades Infecciosas